Pulmonary Edema Market - Forecast(2024 - 2030)

Pulmonary Edema Market size is estimated to be $10 billion in 2019, growing at a CAGR of 7% during the forecast period 2020-2025. Rapid urbanization, changing lifestyle, wrong eating habits, obesity and cardiovascular disease, increasing demand of early detection and diagnosis is a major factor driving the Pulmonary Edema Market during the forecast period 2020-2025.Moreover, pulmonary edema is a condition caused by excess fluids in the lungs. The fluids collect in the numerous air sacs in the lungs making it difficult to breathe. Furthermore, according to the National Heart, Lung and Blood Institute Atherosclerotic Risk in Communities (ARIC) study and Cardiovascular Health Study(CHS) there are 1,260,000 new and recurrent coronary attacks per year- about 37% people experience coronary attack in a given year die from it. Furthermore the use of intra-ventricular septum contributing to the pumping function of left ventricle, lung parenchyma leading to lung diseases, increase in hypertensive crisis, pulmonary shunt and the use of arterial blood gas to measure the amount of arterial gases such as oxygen and carbon dioxide is further driving its market growth.

The report: “Pulmonary Edema Market Forecast (2020-2025)”, by IndustryARC, covers an in-depth analysis of the following segments of the Pulmonary Edema Market.

By Type- Heart-related Pulmonary Edema and Non-heart-related pulmonary Edema.

By Type of Diagnosis- Chest X-Ray, Pulse Oximetry, Blood Test, Imaging and others.

By Treatment- Preload Reducers, After Load Reducers, Heart Medication, Morphine, Suction Catheter and others.

By End-Use-Hospitals, Clinics, Diagnostic Centers, Retail Pharmacies and others.

By Geography-North America, Europe, Asia-Pacific and Rest of the World.

By Treatment- Segment Analysis 

By Treatment, Morphine accounted for the largest market share in 2019 owing to its benefit to relieve shortness of breath and anxiety. Furthermore, it has been used in patients with acute pulmonary edema owing to its anticipated anxiolytic and vasodilatory properties. Moreover, preload reducers is also gaining traction owing to its reduced pulmonary venous return decreases pulmonary capillaries hydrostatic pressure and reduces fluid transudation into the pulmonary interstitium and alveoli. In addition pre-load reducers include NTG drug which provides excellent and reliable preload reduction and high dosage provide mild afterload reduction thereby driving the demand of Pulmonary Edema Market.

Hospitals accounted for the largest market share in 2019 owing to the increasing number of pulmonary edema patients around the world. Furthermore, trained doctors in the hospitals usually perform ECG test, Cardiac MRI and others thereby hospital are a major place for treatment. Furthermore,  technological advancement leading to rapid diagnostic test which are faster, more reliable, and more widely available are further driving the pulmonary edema market during the forecast period 2020-2025.Moreover, the growth of this segment is majorly owing to the increasing number of test in diagnostic centers and hospitals. 

North America dominated the Pulmonary Edema Market with a region share 39% in 2019 followed by Europe. Growing geriatric population along with the rising pulmonary edema, growing health problems along with the rising demand of advanced treatment and a better healthcare system is a significant factor contributing to its market growth. Furthermore, the presence of large number of clinics and ease of availability of technology advanced instruments in that region is further driving its market growth. Moreover, according to the Centers for Disease Control and Prevention about 647,000 Americans die from heart disease each year-that is 1 in every-4 deaths.

Increasing incidence of chronic diseases leading to diabetes and other cardiovascular diseases is a major driving the Pulmonary Edema Market during the forecast period 2020-2025.Futhermore, the growing diabetes patients and their adaptability to different types of treatment is driving the demand of Pulmonary Edema Market during the forecast period 2020-2025. Moreover, according to the World Health Organization about 422 million people worldwide have diabetes particularly in low and middle-income countries and 1.6 million deaths are directly attributed to diabetes each year.

Increase in road accidents leading to severe injury to chest is a major factor driving the Pulmonary Edema Market during the forecast period 2020-2025.Futhermore, automobile crashes represent the most common mechanism of injury resulting into alveolar hemorrhage, consolidation and edema leading to decreased lung compliance. Moreover, according to Association of Safe International Road Travel the economic and societal impact of road crashes cost U.S. citizens $871billion.

Adverse Effect of Available Drugs serves as a major setback for the growth of the Pulmonary Edema Market during the forecast period 2020-2025.Moreover, according to the Drug Induced Pulmonary Toxicity more than 600 drugs are known to cause pulmonary toxicity and illicit drugs are well-known to result in pulmonary toxicities thereby restraining the Pulmonary Edema Market.

Product Launches, Mergers & Acquisitions, joint ventures and R&D activities are key strategies adopted by the players in Pulmonary Edema Market. Pulmonary Edema Market top 10 companies are Pfizer Inc., Argon Medical, Edward Lifesciences Corporation, BD, Lupin Pharmaceuticals Inc., Novartis AG, Gilead Sciences Inc., Merck & Co, Jazz Pharmaceuticals Plc and Sage Therapeutics.